RxDoctor Payments Data

Rachit Marwaha, MD

Internal Medicine · Naperville, ILNPI 1285168526

Payments from drug & device makers

$19,602in general payments, 2019–2025

Across 706 payments — averaging $27.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • AstraZeneca$900
  • Novo Nordisk$801
  • Johnson & Johnson$776
  • Lilly USA, LLC$696
  • Amgen$624
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$7,00036%
  • Food & beverage$12,47564%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)59$8,420
AstraZeneca44$900
Novo Nordisk56$801
Johnson & Johnson49$776
Lilly USA, LLC40$696
Amgen(2 entities)35$624
Nestle Healthcare Nutrition Inc.55$583
GSK32$539
Boehringer Ingelheim29$508
Bayer21$471
Corcept Therapeutics22$416
Xeris Pharmaceuticals, Inc.18$358
Pfizer17$347
Aimmune Therapeutics, Inc.31$308
Otsuka America Pharmaceutical, Inc.11$260
Amarin Pharma, Inc.14$237
Novartis11$185
Dexcom, Inc.9$158
Astellas Pharma US Inc7$147
Kowa Pharmaceuticals America, Inc.10$145
Phathom Pharmaceuticals, Inc.11$135
Merck9$135
Sanofi Pasteur Inc.5$131
Verona Pharma, Inc.3$128
Exact Sciences5$108
Watermark Medical, Inc.1$100
Recordati_rare_diseases_inc.4$99
Sanofi-aventis U.S. LLC6$97
Insulet Corporation3$94
Biohaven Pharmaceutical Holding Company Ltd.3$87
Abbott4$83
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$83
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$77
Ascensia Diabetes Care US Inc.3$76
Eisai Inc.4$74
Teva Pharmaceuticals USA, Inc.5$73
Indivior Inc.3$69
Optos, Inc.3$68
Si-bone, Inc.2$64
Otsuka Pharmaceutical Development & Commercialization, Inc.3$61
Shield Therapeutics Inc3$59
Takeda Pharmaceuticals U.S.A., Inc.3$59
Esperion Therapeutics, Inc.3$57
Boston Scientific3$55
E.r. Squibb & Sons, L.L.C.3$53
Orexo US, Inc.3$45
Neurocrine Biosciences, Inc.2$40
Biodelivery Sciences International, Inc.3$40
Hikma Pharmaceuticals USA2$34
Actelion Pharmaceuticals US, Inc.1$33
Sunovion Pharmaceuticals Inc.2$31
Mylan Specialty L.p.2$26
Inspire Medical Systems, Inc.1$23
Tonix Medicines, Inc.1$23
BETA Bionics, Inc.1$22
Agile Therapeutics, Inc.1$21
Azurity Pharmaceuticals, Inc.1$19
Sumitomo Pharma America, Inc.1$19
Braeburn Inc.1$19
USWM, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,602 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$220,153
Medicare patients
331
Services billed
2,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$90,311
OzempicSemaglutide56$60,600
XareltoRivaroxaban42$46,726
EliquisApixaban42$44,719
TrulicityDulaglutide20$29,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$28,240
FarxigaDapagliflozin Propanediol22$26,246
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$18,867
JanuviaSitagliptin Phosphate11$16,659
JanumetSitagliptin Phos/Metformin Hcl13$11,926
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$4,438
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,877
PaxlovidNirmatrelvir/Ritonavir18$2,829
Pravastatin Sodium120$2,287
Gabapentin155$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$508$90,31156 claims
Novo NordiskOzempic$801$60,60056 claims
PfizerEliquis, Paxlovid$347$47,54960 claims
Johnson & JohnsonXarelto$776$46,72642 claims
Lilly USA, LLCTrulicity$696$29,06620 claims
MerckJanuvia, Janumet$135$28,58624 claims
GSKTrelegy Ellipta$539$28,24024 claims
AstraZenecaFarxiga$900$26,24622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →